CIK 0001677077 · <br>Emerging growth company
Alzamend Neuro, Inc.
Sign in to watch- Ticker
- ALZN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811822909
- Phone
- 844-722-6333
- Business address
- 480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
- SC 13D/A Stake Beneficial Ownership Report
- 4 Other disposition Director disposed of 661,168 shares (other)
- 4 Open-market buy Director bought 5,000 shares at $1.02 ($5,093)
- 8-K Event Executive or director change
- 4 Open-market buy 10% owner bought 700 shares at an average $0.91 ($635)
- 10-Q Report Quarterly Report
- 8-K Event Regulation FD disclosure
- 8-K Event Bylaws or fiscal year change · Regulation FD disclosure
- 8-K Event Delisting notice · Shareholder vote results
- 4 Open-market buy Chief Financial Officer bought 53,000 shares at $0.19 ($10,234)
- 8-K Event Regulation FD disclosure
- 10-Q Report Quarterly Report
- 424B5 Offering Prospectus
- 8-K Event Material agreement
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 8-K Event Other events
- EFFECT Other Notice of Effectiveness
- PRE 14A Proxy Proxy Statement (Preliminary)
- CORRESP Other Correspondence Between Filers and SEC Staff
Page 8 of 20 · 398 filings